Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Sutherland L, Macdonald JK.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD000544. Review. Update in: Cochrane Database Syst Rev. 2012;10:CD000544.

PMID:
16625537
2.

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Wang Y, Parker CE, Feagan BG, MacDonald JK.

Cochrane Database Syst Rev. 2016 May 9;(5):CD000544. doi: 10.1002/14651858.CD000544.pub4. Review.

PMID:
27158764
3.

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK.

Cochrane Database Syst Rev. 2016 Apr 21;4:CD000543. doi: 10.1002/14651858.CD000543.pub4. Review.

4.

Aminosalicylates for induction of remission or response in Crohn's disease.

Lim WC, Wang Y, MacDonald JK, Hanauer S.

Cochrane Database Syst Rev. 2016 Jul 3;7:CD008870. doi: 10.1002/14651858.CD008870.pub2. Review.

PMID:
27372735
5.

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.

Timmer A, Patton PH, Chande N, McDonald JW, MacDonald JK.

Cochrane Database Syst Rev. 2016 May 18;(5):CD000478. doi: 10.1002/14651858.CD000478.pub4. Review.

PMID:
27192092
6.

Curcumin for maintenance of remission in ulcerative colitis.

Kumar S, Ahuja V, Sankar MJ, Kumar A, Moss AC.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD008424. doi: 10.1002/14651858.CD008424.pub2. Review.

7.

Aminosalicylates for induction of remission or response in Crohn's disease.

Lim WC, Hanauer S.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD008870. doi: 10.1002/14651858.CD008870. Review. Update in: Cochrane Database Syst Rev. 2016;7:CD008870.

PMID:
21154400
8.

Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease.

Akobeng AK, Zhang D, Gordon M, MacDonald JK.

Cochrane Database Syst Rev. 2016 Sep 28;9:CD003715. [Epub ahead of print] Review.

PMID:
27681657
9.

The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.

Bonapace CR, Mays DA.

Ann Pharmacother. 1997 Jul-Aug;31(7-8):907-13. Review.

PMID:
9220055
10.
11.

[Mesalazine old and new].

Mañosa M, Domènech E.

Gastroenterol Hepatol. 2011 Dec;34 Suppl 3:25-9. doi: 10.1016/S0210-5705(11)70095-4. Epub 2014 Oct 30. Review. Spanish.

PMID:
25443223
12.

Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis.

Fleig WE, Laudage G, Sommer H, Wellmann W, Stange EF, Riemann J.

Digestion. 1988;40(3):173-80.

PMID:
2906888
13.

Different therapy for different types of ulcerative colitis in China.

Jiang XL, Cui HF.

World J Gastroenterol. 2004 May 15;10(10):1513-20.

14.

[Therapeutic efficacy of 5-ASA molecules in idiopathic intestinal inflammatory diseases: critical review].

Van Gossum A.

Acta Gastroenterol Belg. 1992 Sep-Dec;55(5-6):462-71. Review. French.

PMID:
1363167
15.

Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.

Böhm SK, Kruis W.

Clin Exp Gastroenterol. 2014 Sep 23;7:369-83. doi: 10.2147/CEG.S35691. eCollection 2014. Review.

16.

5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis.

Walker AM, Szneke P, Bianchi LA, Field LG, Sutherland LR, Dreyer NA.

Am J Gastroenterol. 1997 May;92(5):816-20.

PMID:
9149192
17.

Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases.

Kandula M, Sunil Kumar KB, Palanichamy S, Rampal A.

Int Immunopharmacol. 2016 Nov;40:443-451. doi: 10.1016/j.intimp.2016.09.013. Epub 2016 Oct 4.

PMID:
27716592
18.

The role of aminosalicylates in the treatment of ulcerative colitis.

Van Assche G, Baert F, De Reuck M, De Vos M, De Wit O, Hoang P, Louis E, Mana F, Pelckmans P, Rutgeerts P, Van Gossum A, D'Haens G.

Acta Gastroenterol Belg. 2002 Oct-Dec;65(4):196-9.

PMID:
12619425
19.

Duration of treatment with 5-aminosalicylic acid compounds.

Moshkovska T, Mayberry JF.

World J Gastroenterol. 2007 Aug 28;13(32):4310-5. Review.

Supplemental Content

Support Center